publication date: Oct. 5, 2018

In Brief Ruth O’Regan named chief scientific officer of Big Ten Cancer Research Consortium

Ruth O’Regan was named chief scientific officer of the Big Ten Cancer Research Consortium.

O’Regan is the division head of hematology, medical oncology and palliative care in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health and associate director for clinical research at the UW Carbone Cancer Center.

An active member of the Big Ten CRC’s Breast Clinical Trial Working Group,  O’Regan is the sponsor-investigator of the consortium’s BTCRC-BRE15-024 , a new approach to triple-negative breast cancer.

The trial is also open at the cancer centers at the University of Illinois, Michigan State, Penn State, and Rutgers.

O’Regan will serve a renewable three-year term as CSO. In this role, she will guide the research and scientific mission of the consortium, the most promising clinical trials to be conducted through the consortium.

O’Regan will serve as the primary spokesperson for the research and scientific activities of the consortium, and she will support the Steering Committee and Clinical Trial Working Groups in their interactions with the biotech and pharmaceutical industry.

Before she joined the UW Carbone Cancer Center in 2015, O’Regan was professor of hematology and medical oncology at Emory University … Continue reading Ruth O’Regan named chief scientific officer of Big Ten Cancer Research Consortium

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.